FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington, D.C. 20549	ashington,	D.C.	20549	
-----------------------	------------	------	-------	--

TATEMENT	OF CHANGE	S IN BENEFIC	IAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* COLES N ANTHONY			2. Issuer Name and Ticker or Trading Symbol Cerevel Therapeutics Holdings, Inc. [CERE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
COLES	S N ANII	HUNY			<u> </u>	OT THE	<u>apou</u>	ttios III	<u>OIGI</u>	<u> 1185, 111</u>	<u>v.</u> [CE:	. ,	X Directo	r		10% Ow	ner
(Last)	(F	irst)	(Middle)		Date of Earliest Transaction (Month/Day/Year)								X Officer below)	Officer (give title below)			pecify
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.					10/28/	2020		,		• /			President and CEO				
131 DAF	RTMOUTH	STREET, SUIT	E 502														
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOSTO	N M	ΙA	02116										X Form fi	led by One	Reportir	ng Person	
													Form fi Person	led by More	than Or	ne Report	ing
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transac Date (Month/Da	Execution Date,		Code (Instr.			Beneficia Owned F	s illy ollowing	6. Owne Form: D (D) or In (I) (Instr.	irect I direct E . 4)	7. Nature of Indirect Beneficial Ownership				
					Code V Amount (A) or P			Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year)		of Securities		ties ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(O Fe Illy O (I)	0. ownership orm: irect (D) r Indirect) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	e V			Date Exercisabl		xpiration ate	Title	Amount or Number of Share	.	(Instr. 4)	5(0)		
Stock Option (Right to Buy)	\$9.88	10/28/2020		А		196,335		(1)	1	0/28/2030	Common Stock	196,33	\$0.00	196,33	5	D	

Explanation of Responses:

1. 50% of this option shall vest and become exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter.

Remarks:

/s/ Bryan K. Phillips, as Attorney-in-Fact

10/30/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.